BriaCell opens first Canadian Phase 3 trial site at Sunnybrook’s Odette Cancer Centre in Toronto

• BriaCell opened its first Canadian clinical site at Sunnybrook’s Odette Cancer Centre for its pivotal Phase 3 metastatic breast cancer trial.
• The Bria-ABC study tests Bria-IMT with an immune checkpoint inhibitor versus physician’s choice; primary endpoint is overall survival.
• U.S. enrollment footprint exceeds 80 active sites across 15 states; Canadian launch expands patient access outside the U.S.
• Interim analysis planned once 144 patient deaths occur, comparing mortality between the combination regimen and physician’s choice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160730PRIMZONEFULLFEED9763191) on July 16, 2026, and is solely responsible for the information contained therein.